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Systemiclupuserythematosusandrheumatoidarthritisaretwomajorchronicinﬂammatoryautoimmunediseaseswithsigniﬁcant
prevalence rates among the population. Although the etiology of these diseases remains unresolved, several evidences support the
key role of CD154/CD40 interactions in initiating and/or propagating these diseases. The discovery of new receptors (αIIbβ3,
α5β1, and αMβ2) for CD154 has expanded our understanding about the precise role of this critical immune mediator in the
physiopathology of chronic inﬂammatory autoimmune diseases in general, and in systemic lupus erythematosus and rheumatoid
arthritis in particular. This paper presents an overview of the interaction of CD154 with its various receptors and outlines its
role in the pathogenesis of systemic lupus erythematosus and rheumatoid arthritis. Moreover, the potential usefulness of various
CD154-interfering agents in the treatment and prevention of these diseases is also discussed.
1.Introduction
Over the last decade, considerable new insights into the
pathogenesis of systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) have been provided. SLE involves
the production of autoantibodies against many self antigens,
and the formation of immune complexes aﬀecting many
tissues and organs. RA, on the other hand, mainly implicates
joints and articulations, where chronic inﬂammation of the
synovial tissues leads to destructive tissue damage. Mecha-
nistically, interactions between the extracellular matrix, cell
surface receptors, and soluble mediators are at the center of
the inﬂammatory response that takes place in these autoim-
mune diseases. Indeed, most of the new biological therapies
currently in use or in clinical development are directed at
membrane associated targets or their ligands. In this matter,
CD154, in its membrane-bound or soluble form, was shown
to be an important modulator of immunoinﬂammatory
events in autoimmune diseases [1]. Here we review the
major and most recent ﬁndings on the role of CD154 in
various inﬂammatory autoimmune diseases, while focusing
in particular on SLE and RA. Accumulating knowledge will
allowustobetterunderstandtheCD154axisindiseasestates,
thereby, facilitating the design of new preclinical approaches
and more eﬃcient therapies for the treatment of CD154-
associated pathologies.
2.CD154
CD154, also known as CD40 ligand (CD40L), previously
referred to as gp39, TRAP, or TBAM [2–4], is a 39kDa type
II membrane glycoprotein of the TNF family [5]. Located
on the long arm of the X chromosome, region q26.3–q27.1,
the human CD154 gene is composed of ﬁve exons and
four introns. It encodes a polypeptide of 261 amino acids
(aa), consisting of a 215aa extracellular domain, a 24aa
transmembrane region, and a 22aa cytoplasmic tail [6–
9]. Like other members of the TNF-family, CD154 forms
a trimeric structure and promotes as such trimerization
of the receptor, namely, CD40 [10]. The CD154/CD40
interactionisstabilizedbychargedresidues,namely,thebasic
chains on CD154 and the acidic ones on CD40 [11, 12].2 Clinical and Developmental Immunology
It has been reported that the CD154/CD40 interaction is
required for the proteolysis of membrane-bound CD154
and the subsequent release of soluble CD154 (sCD154) by
activatedplatelets[13].SolubleCD154isan18kDafragment
comprised of residues 113–261 of the membrane-bound
CD154 molecule and remains a functional trimer retaining
its ability to bind receptors. Indeed, sCD154 shares similar
activities with the membrane bound form and has been
shown to be associated with many autoimmune diseases
[14]. The CD154 homotrimer is nonconstitutively expressed
on diﬀerent cell types, including activated T lymphocytes,
basophils, eosinophils, monocytes, macrophages, natural
killer cells, B lymphocytes, platelets, dendritic cells, as well
as endothelial, smooth muscle, and epithelial cells [14].
Accumulating evidence now indicates that CD154 can
bind to receptors other than CD40, namely, the integrins
αIIbβ3, α5β1, and αMβ2[ 15–19].
3.CD154Receptors
3.1. CD40. CD40 is a 48kDa type I membrane glycoprotein
a n dm e m b e ro ft h et u m o rn e c r o s i sf a c t o rr e c e p t o r( T N F R )
super family [5]. The human CD40 gene was localized to
the long arm of chromosome 20 along 2q12–q13.2. [20],
and Tone et al. have showed that it contains 9 exons [21].
Transcription of the gene yields a phosphoprotein of 277
amino acids composed of a signal peptide, an extracellular
domain including 22 cysteine residues implicated in its
ligand binding, two potential N-linked glycosylation sites,
a transmembrane region central for its translocation and
clustering into lipid rafts microdomains, and a cytoplasmic
region [11, 22–25].
The precise structure by which CD40 is found on the cell
surface is still a matter of controversy. Despite the initial sug-
gestion that CD40 exists as a dimer that is being trimerized
upon CD154 ligation, more recent studies describe CD40
as a constitutively preassembled trimer [26]. Moreover, we
have shown that upon CD154 ligation, CD40 can oligomer-
ize into dimers between cysteine residues 238 located in
the intracellular region of the molecule. Interestingly, this
dimerization appears essential for phosphoinositide-3 kinase
(PI-3K) activation and the subsequent activation of B7.2,
as well as the production of IL-8 in B cells. Recently, the
CD154/CD40 complex has been described as a trimeric
CD154 molecule interacting with a CD40 dimer, as the third
CD40 molecule is pushed out of the complex by charged
residues [12]. Hence, additional studies are required for
further clariﬁcation of the exact structure of CD40 on the
cell surface.
CD40 is constitutivelyexpressed on a widevariety ofcells
including B cells, dendritic cells, macrophages, endothelial
cells, ﬁbroblasts, platelets, osteoblasts, smooth muscle cells,
neurons, pancreatic beta cells, and ductal cells. CD40 was
also shown to be induced by various cytokines such as
TNF-α and interleukin-1β (IL-1β)i nav a r i e t yo fc e l lt y p e s
[9,27].Uponitsengagement,CD40inducesapatternofgene
expression depending on the particular cell type involved.
On B cells, it is critical for survival and proliferation, isotype
switching, germinal center formation, memory generation,
and production of numerous cytokines and chemokines
such as IL-1, IL-6, IL-8, IL-10, IL-12, TNF-α, and cytotoxic
radicals. On T cells, CD40 can inﬂuence cell priming and
cell-mediated eﬀector functions including macrophage and
natural killer cell activation [14]. On vascular endothelial
cells, CD40 stimulates cytokine production, upregulation
of adhesion molecules, release of superoxide anions, and
expressionofcyclooxygenase-2[1,28,29].Ondendriticcells,
monocytes and macrophages, CD40 stimulates the produc-
tion of cytokines such as TNF and contributes to the rescue
ofcirculatingmonocytesfromapoptosis [14](Figure 1).The
extensive distribution and various inﬂammatory functions
of the CD154/CD40 axis explain its involvement in the
pathogenesis of many autoimmune diseases.
3.2. αIIbβ3. The αIIbβ3 integrin, also known as GPIIb/IIIa,
is a major platelet integrin of critical importance for platelet
adhesion, aggregation, and thrombus formation. When
activated by “inside out” signaling, in response to various
platelet agonists (thrombin, collagen, ADP, or epinephrine),
αIIbβ3 will change its conformation allowing binding of
its major ligands, including ﬁbrinogen, ﬁbronectin, and
von Willebrand factor [30]. Binding is mediated through
the RGD sequence found on many αIIbβ3 ligands. Inter-
estingly, CD154 was also found to interact with αIIbβ3,
primarily through the RGD sequence contained within
the extracellular portion of the CD154 molecule. Binding
of CD154 to αIIbβ3 induces phosphorylation of tyrosine
residues within the cytoplasmic domain of the β3 chain and
appears necessary for stability of arterial thrombi [31]. These
ﬁndings demonstrate that CD154, through its interaction
with αIIbβ3, is a platelet agonist that functions in an
autocrine manner to regulate platelet biology (Figure 2).
3.3. α5β1. The α5β1 integrin has recently been identiﬁed
as a novel functional receptor for CD154 [32]. Like αIIbβ3,
active α5β1 binds to its classical ligands ﬁbrinogen and
ﬁbronectin through their RGD sequence [30]. Interestingly,
wehavepreviouslyshownthatCD154bindstoinactiveα5β1.
In addition, we demonstrated that simultaneous binding
of CD154 to CD40 and α5β1 is possible, indicating that
CD154 interacts with α5β1 outside the CD40-binding site.
The binding of CD154 to a monocytic cell line expressing
α5β1 leads to the phosphorylation of the extracellular signal
regulated kinase 1/2 (ERK1/2) and the expression of IL-
8 mRNA in these cells, which is indicative of a functional
consequence of the CD154/α5β1 interaction [32]( Figure 2).
Even though α5β1 is expressed on endothelial cells, smooth
muscle cells, and platelets, its role upon interacting with
CD154 in these cells has not been elucidated yet.
3.4. αMβ2( M a c - 1 ) .AlphaMβ2 or Mac-1 (CD11b/CD18),
a member of the integrin family mainly expressed on
monocytes/macrophages and neutrophils, has also recently
been identiﬁed as a CD154 receptor [19]. As with its
classical ligands, such as C3bi [33], intracellular adhesion
molecule-1 [34], ﬁbrinogen [35], vitronectin [36], factor
Xa [37, 38], heparin [39, 40], glycoprotein Ibα [41, 42],Clinical and Developmental Immunology 3
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Figure 1: Biological function of the CD154/CD40 interaction. CD154 mediates numerous inﬂammatory functions on a wide variety of
cell types by interacting with its classical CD40 receptor. These include T cell priming, B cell-dependent Ig class switching and germinal
center formation, cell proliferation, regulation of apoptosis, release of proinﬂammatory cytokines, upregulation of adhesion molecules
and costimulatory molecules, and production of cytotoxic radicals. FB: ﬁbroblast, EC: endothelial cell, APC: antigen presenting cells, DC:
dendritic cell, MC/Mac: monocyte/macrophage.
junctional adhesion molecule-3 [43], and lipoproteins [44],
only the active conformation of Mac-1 can interact with
CD154. This pleiotropic binding ensues Mac-1 a role in
immune responses, coagulation, and inﬂammation [45].
Indeed, Zirlik et al. demonstrated that CD154 function-
ally enhances monocyte adhesion and migration via its
binding with Mac-1 on monocytes. Interestingly, CD154
stimulation was shown to trigger Mac-1-dependent nuclear
factor-kB (NFkB) activation and enhance myeloperoxidase
release from monocytes [19]( Figure 2). In addition, the
CD154/Mac-1 interaction may play a signiﬁcant role in
atherogenesis, since Mac-1 inhibition in the LDLR−/−
atherosclerosis mouse model attenuates arterial plaque
development and lesional macrophage accumulation [19].
Furthermore, Li et al. showed that CD154 upregulates
Mac-1 expression on neutrophils and enhances leukocyte
recruitment and neointima formation after arterial injury in
ApoE−/− mice, another atherosclerosis-prone mouse model
[46]. These ﬁndings unravel a novel mechanism by which
CD154 contributes to inﬂammatory events at the level of
vascular cells.
4.CD154 inAutoimmune Diseases
CD154 contributes to the potentiation of autoimmune
diseases in which B and T cell activation plays a major role,
such as SLE, RA, lupus nephritis, multiple sclerosis, and
autoimmune diabetes [47]. Indeed, a role for CD154/CD40
interactions have been identiﬁed in the development of
Type I diabetes [48]. Moreover, signaling through CD40 was
shown to induce the production of inﬂammatory cytokines
in human and nonhuman primate islet cells [49]. High
expression of CD154+ cells was also detected in the brains
of patients with multiple sclerosis [47]. In addition, patients
with psoriatic arthritis were found to exhibit CD40 expres-
sion on keratinocytes and endothelial cells within psoriatic
plaques and increased expression of CD154 on peripheral
blood T cells [50–52]. Increased levels of soluble CD154
were also reported in patients with SLE, RA, and Sjorgren’s
disease, in association with disease activity [53]. In fact,
the CD154/CD40 interaction triggers a series of immune
responses contributing to T-cell-dependent immunity at
diﬀerent levels in these diseases [54]. First, CD154 signaling
could disrupt negative selection in the thymus allowing
escape of self-reactive T cells and thus failure of central
tolerance.Second,aberrantCD154-dependentproductionof
proinﬂammatory cytokines could direct the diﬀerentiation
of T cells to Th17 cells, a process that is augmented by acti-
vation of antigen-presenting cell. Third, CD154 interactions
could stimulate inﬂammatory chemokines and cytokines
within the target tissue, which contribute to tissue damage
and propagation of the inﬂammatory assault [49, 55–58].
This review will focus primarily on recent ﬁndings
concerning the role of CD154 in SLE and RA.4 Clinical and Developmental Immunology
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Figure 2: Structural and functional characteristics of CD154 receptors. Four receptors for CD154 have been identiﬁed, namely, CD40,
αIIbβ3, α5β1, and αMβ2. These receptors are found on various cell types and induce diﬀerent biological functions upon CD154 binding.
APC: antigen presenting cells, DC: dendritic cells, MC: monocyte, EC: endothelial cell, FB: ﬁbroblast, SMC: smooth muscle cell, Mac:
macrophage, ICAM: intercellular adhesion molecule, GPIbα:g l y c o p r o t e i nI b α, JAM-3: junctional adhesion molecule-3, MPO: myelo-
peroxidase.
4.1. Systemic Lupus Erythematosus (SLE). SLE is a multior-
gan target autoimmune disease characterized by a defect in
the innate and adaptive immune systems, in which B cells
are at the center of the pathogenesis. Indeed, B cells, with
the aid of CD4+ T cells, secrete autoantibodies, activate the
complement system, and favor the production of cytokines
and other mediators potentially involved in inﬂammation,
tissue damage, and progression of the disease [59]. Central
to all these processes is signaling events mediated by CD154
[60, 61].
4.1.1. Role of CD154 in Pathogenesis of SLE. CD154 is over-
expressed on T cells and atypically expressed on B cells
and monocytes in patients with active SLE [62–64]. Ectopic
expression of CD154 on B cells is also observed in lupus-
p r o n eB X S Bm i c e[ 65]. Higushi et al. demonstrated that
CD154-transgenic mice spontaneously produce autoanti-
bodies such as anti-DNA Abs and develop lupus like
glomerulonephritis with age [66]. Immunohistochemical
analysis of CD154 expression in the biopsies of lupus kidney
specimens showed an upregulation of CD154 expression
on renal endothelial and tubular cells, and on interstitial
inﬁltrating T cells [60]. Moreover, CD154 was shown to
contribute to SLE pathogenesis by inducing the production
of various chemokines in renal endothelial and tubular cells,
thereby, increasing local inﬂammatory responses [67, 68].
The abnormally prolonged expression of CD154 on T cells
and high levels of circulating sCD154 can activate bystander
autoimmune B cells and initiate autoantibody secretion in
SLE (Figure 3). Moreover, the enhanced CD154 expression
on activated T cells is implicated in the overexpression of
costimulatory molecules such as CD86 on B cells isolated
from SLE patients. CD154-induced overexpression of CD86
is essential for anti-DNA antibody production in these
patients [69]. In addition, it has been suggested that the
atherosclerotic complications seen in patients with SLE are
mediatedbyCD154anditsreceptors[70,71].Infact,CD154
on activated platelets derived from patients with SLE can
upregulate the expression of CD40 on mesangial cells and
induce the release of soluble CD40. Such CD154-mediated
responses activate mesangial cells, thus, stimulating their
proliferation and production of TGF-β1[ 72]. Interestingly,
these responses are associated with glomerular injury and
glomerulosclerosis in SLE, respectively.
4.1.2. Serum Levels of CD154 in SLE Patients. Circulating
levels of sCD154 in patients with SLE correlate with the titers
of anti- double-stranded DNA (dsDNA) autoantibodies and
with disease activity [73, 74]. Soluble CD154, at concen-
trations reported in some SLE sera, is capable of inducing
the upregulation of several accessory molecules on B cells,
w h i c hf a v o r sBc e l ls u r v i v a la n dd i ﬀerentiation, thereby,
exacerbating the immune response [74]. Moreover, SLE
patients exhibiting antiphospholipid antibodies in their seraClinical and Developmental Immunology 5
Figure 3: CD154-dependent mechanistic events in SLE patients. High levels of membrane bound and sCD154 activate various immune cells
inSLE,includingTcells,Bcells,andmonocytes.TheseCD154interactionsinducethereleaseofinﬂammatorymediatorsandtheproduction
of autoantibody and Igs, leading to the generation of immune complexes and the activation of the complement system at the forefront of
many clinical manifestations in SLE patients.
and presenting with a history of thrombosis have higher cir-
culatingsCD154levelsthanSLE-antiphospholipidantibody-
positive patients with no history of thrombosis [75]. These
data further support a possible role for the CD154 axis
in the increased vascular events seen in SLE. Moreover,
Aleksandrovaetal.showedthatenhancedlevelsofsCD154in
patientswithSLEandsecondaryantiphospholipidsyndrome
are associated with pronounced intima-media thickness
of the carotid arteries, hypercholesterinemia, and diastolic
dysfunction [76]. These ﬁndings also support the association
of CD154 with cardiovascular abnormalities in SLE.
4.1.3. Anti-CD154 Treatment in SLE. In view of all the sug-
gestedrolesofCD154inSLE,manyapproachesusingCD154
blocking monoclonal antibodies (mAbs) have been tested
in murine models of the disease and resulted in positive
outcomes.Treatmentwithanti-CD154mAbspriortodisease
onset prevents proteinuria, prolongs survival, ameliorates
or even prevents kidney disease, and decreases anti-DNA
autoantibody titers in the New Zealand Black/New Zealand
White F1 systemic lupus erythematosus (NZBxNZW) F1
and (SWRxNZB) F1 mice models. Moreover, anti-CD154
treatment when nephritis has already developed still slows
disease progression, reverses proteinuria, and induces remis-
sions in mice, despite ongoing renal immune complex
deposition. Responding mice show rapid downregulation of
TNF-α, IL-10, and TGF-β mRNA levels [77, 78]. In addition,
a short-term combination therapy with the costimulatory
antagonistsCTLA4-Igandanti-CD154inNZB/NZWF1mice
delays the onset of renal dysfunction, signiﬁcantly decreases
the frequency of B cells producing anti-DNA IgGs, partially
suppresses class switching, and inhibits T cell activation and
switching to memory phenotypes [79].
To date, two clinical studies investigating the use of anti-
CD154 mAbs for the treatment of SLE have been conducted.
In clinical trials, ruplizumab (BG9588) showed good clinical
and laboratory responses in some SLE patients. However,
the study was stopped earlier than expected because of
thromboembolic events [80]. Toralizumab (IDEC-131) was
testedinadouble-blind,placebo-controlledstudyinpatients
with mild-to-moderately active SLE over 16 weeks. although
the systemic lupus erythematosus disease activity index
(SLEDAI) scores improved from the baseline levels of disease
activityinallgroups,thesescoreswerenotstatisticallysignif-
icant among the IDEC-131 treated and placebo groups [61].
New reagents inhibiting CD154-mediated events without
increasing the risk of thromboembolic complications are in
development [81]. It is important to note at this level that
developing new CD154 interfering agents should take into
account the new receptors identiﬁed for CD154 [1].
4.2. Rheumatoid Arthritis (RA). RA is a chronic, progressive,
and debilitating autoimmune disease that occurs in approxi-
mately 1% of adults. A vicious cycle of inﬂammation
and cartilage destruction is at the hallmark of the ongo-
ing autoimmune reactions in the synovial tissue. Syno-
vial inﬂammation, pannus formation, neoangiogenesis, and
destruction of joint cartilage are mediated by the con-
stant synthesis of matrix metalloproteinases (MMPs) and
proinﬂammatory cytokines, such as TNF-α and IL-1. The6 Clinical and Developmental Immunology
Figure 4: Biological role of CD154 in RA. CD154 contributes to the pathogenesis of RA by stimulating expression of adhesion molecules,
production of RF, release of inﬂammatory mediators including cytokines, chemokines, MMPs, and others.
inﬁltrating leukocytes and synovial cells destroy the cartilage
tissue and erode bones, thereby, resulting in the loss of
articular surfaces and joint motion [82].
4.2.1. Role of CD154 in the Pathogenesis of RA. Many reports
have demonstrated the implication of CD154 and CD40 in
the pathogenesis of RA. In fact, CD154 is implicated in all
pathogenic events of RA that ultimately lead to cartilage
destruction and bone erosion. These include the T cell-
mediatedresponse,thepresenceofrheumatoidfactors(RFs),
the expression of adhesion molecules, synovial hyperplasia,
and pannus formation, as well as the secretion of proin-
ﬂammatory cytokines and MMPs (Figure 4). The enhanced
expression of CD154 on T cells supports the theory of a T-
cell-drivendisease.CD154mRNAandproteinwereshownto
be upregulated on peripheral blood and synovial ﬂuid T cells
from RA patients, in comparison to control patients [83]. In
addition, CD154 as well as CD40 are overexpressed by CD4+
and CD8+ T lymphocytes and macrophages of the synovial
ﬂuid of rheumatoid patients. This aberrant expression was
postulated to contribute to the development of synovial
hyperplasia [84, 85]. It was also suggested that the increased
and prolonged expression of CD154 on T cells from RA
patients might be contributing to enhanced cell function and
articular inﬂammation [85, 86].
The inﬂammatory process in RA is dependent on both
humoral- and cell-mediated immunity. CD154 on activated
T cells is linked to RF synthesis [87], B cell-dependent IgG
overproduction, and secretion of IL-12 by synovial dentritic
cells and macrophages [85, 88, 89]. On the other hand,
CD154 expressed on T lymphocytes induces other critical
costimulatory molecules, namely, CD80 and CD86 on B
cells, macrophages, and dendritic cells, which in turn can
favor T cell activation. Activated T cells can then initiate
speciﬁc cellular immune responses, through the secretion of
proinﬂammatory cytokines. For instance, the CD154/CD40
interaction was shown to increase the production of TNF-α,
which plays a major role in the pathogenesis of RA. Indeed,
Harigai et al. demonstrated that ligation of CD40 on freshly
isolated synovial cells, using a recombinant sCD154 protein,
induced TNF-α and IL-1β production, a response further
ampliﬁed by IFNγ [88].
Other investigators have also demonstrated that ligation
of CD40 on CD68+ synovial macrophage cells as well
as ﬁbroblast-like synoviocytes enhances the expression of
CD154, CD106, IL-6, stromal cell-derived factor 1, vascular
endothelial cell growth factor (VEGF), IL-8, and regu-
lated upon activation normal T-cell expressed and secreted
(RANTES) [84, 90–95]. In addition, ligation of CD40 on
synovial ﬁbroblasts from RA patients by T cell CD154Clinical and Developmental Immunology 7
was shown to stimulate neovascularization at the site of
synovitis by enhancing VEGF protein and mRNA levels
[96]. Moreover, the CD154/CD40 axis is directly linked to
the inﬂammatory process by increasing the expression of
important adhesion molecules on ﬁbroblastic cells, such
as E selectin, vascular cell adhesion molecule-1 (VCAM-
1), and intercellular adhesion molecule-1 (ICAM-1). These
responsestherebyexacerbatetherecruitmentandinﬁltration
of immune cells at the sites of inﬂammation [91]. CD154
further contributes to a deleterious degradative cycle in RA
by inducing the expression and activation of MMPs (MMP-
1, MMP-9, and MMP-3) [97, 98], which are well known to
drive the degradation of extracellular matrix proteins in RA.
Hence, it is now believed that CD154, through its
involvement in the production of chemokines, cytokines,
MMPs, adhesion molecules, and growth factors, contributes
to pannus formation and perpetuation of inﬂammation in
RA(Figure 4).Itisalsoworthnoting,thattheCD154/CD40-
dependent induction of inﬂammatory mediators by RA
synovial cells is mediated via the activation of MAPKs,
especially ERK-1/2, p38 and NFκB[ 99].
4.2.2.Serum Levels of CD154 inRAPatients. The importance
of the CD154/CD40 axis in the pathophysiology of RA is
further consolidated by the levels of circulating sCD154
found in patients. Indeed, high levels of sCD154 have been
reported in most patients with juvenile idiopathic arthritis
[100]. Moreover, serum levels of sCD154 are higher in
patients with RA than in healthy subjects and signiﬁcantly
c o r r e l a t ew i t hb o t hI g M - R Fa n dI g G - R Ft i t e r s[ 101].
4.2.3. Anti-CD154 Treatment in RA. CD154/CD40 signaling
was demonstrated to be critical in the initiation and
progression of the mouse collagen-induced arthritis (CIA)
model. Treatment of mice with agonistic anti-CD40 Abs at
the time of CIA induction exacerbates the disease [102].
Conversely, the administration of antagonistic anti-CD154
mAbs prior to induction of CIA signiﬁcantly ameliorates the
disease [103], as manifested by the inhibition of symptoms
such as development of joint inﬂammation, serum antibody
titers to collagen, inﬁltration of inﬂammatory cells into the
subsynovial tissue, and erosion of cartilage and bone in
treated mice [104]. Anti-CD154 treatment in the K/BxN
arthritis mouse model was shown to induce prophylactic
eﬀects, as antibody administration inhibits development in
mice when given before the onset of the clinically apparent
disease [105]. However, anti-CD154 therapy has no eﬀect
when administered after clinical onset. These results support
theCD154axisasatherapeutictargetinthetreatmentofRA.
5. Conclusions andFutureStudies
The current review supports the role of CD154 as a major
participant in the pathogenesis of autoimmune diseases,
particularly RA and SLE. As previously detailed, the CD154
axis, through its diverse distribution on many cell types, has
acquired pleiotropic functions and contributes to inﬂamma-
tory diseases by triggering the secretion of critical inﬂamma-
torymediatorspotentiallyinvolved intissuedegradation and
damage. It is now well established that CD154 interacts with
manyreceptors,namely,CD40,αIIbβ3,α5β1,andαMβ2.For
instance, it can constitutively bind to CD40 and α5β1, as well
astheactiveformsofαIIbβ3andαMβ2.Interestingly,CD154
can simultaneously bind to two receptors expressed on the
same cell surface. This phenomenon may grant CD154 dis-
tinct biological activities, depending on the receptor in ques-
tion and the signaling pathway it might trigger. Even though,
most of the biological functions of CD154 are believed to
involve its interaction with CD40, the discovery of other
receptors for CD154 unravels new roles for this molecule in
mediating immune and inﬂammatory events at the forefront
of the pathogenesis of many diseases including autoimmune
disorders. However, little is known about the signaling path-
ways and cellular responses triggered by the interaction of
CD154withitsotherreceptors.Indeed,theelucidationofthe
precise molecular pathways induced by the CD154/αIIbβ3,
CD154/αMβ2, and CD154/α5β1 interactions will allow a
better understanding of the biological roles of CD154 in
associated diseases and allow the design of better therapeutic
strategies for the management of these disease conditions.
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